Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
bioMérieux S.A. logo

OTC · BMXXY

bioMérieux S.A.

Healthcare · Medical - Specialties

$10.65

Up+$0.00 (+0.00%)

Updated Oct 31, 2026, 8:20 PM

SID Score

4.7/10

Composite research score

Smart Money

46/100

Neutral

Market cap
14.67B
P/E ratio
33.93
Dividend yield
0.97%
52-week range
$7.12 – $14.55
Volume
353
Avg. volume
789

Price performance · BMXXY

BMXXY price history

1M range · 12 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

BMXXY closed at $10.65 after 12 trading sessions, up 17.80% for the selected period.

Last close
$10.65
Period change
+17.80%
Period low
$8.80
Period high
$11.29
Daily close
View OHLC price history
BMXXY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$10.65$10.65$10.65$10.65353
Oct 28, 2026$11.2925$11.2925$11.2925$11.2925655
Oct 26, 2026$10.4299$10.4299$10.4299$10.4299130
Oct 15, 2026$10.096$10.19$10.096$10.19681
Oct 14, 2026$9.98$9.98$9.98$9.981.32K
Oct 12, 2026$9.74$9.74$9.74$9.74817
Oct 9, 2026$9.69$9.69$9.065$9.4598739
Oct 8, 2026$9.53$9.90$8.929$8.9293.08K
Oct 7, 2026$9.383$9.46$9.035$9.461.35K
Oct 6, 2026$9.30$9.30$8.97$8.971.36K
Oct 5, 2026$9.136$9.14$8.525$8.803.06K
Oct 2, 2026$9.041$9.041$9.041$9.041436

Latest BMXXY news

The latest Smart Investors Daily articles mentioning BMXXY.

Stock researchCompany · Overview

BMXXY research

Overview

Company profile and research snapshot.

Company profile

BIOMERIEUX S A UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BMXXY recent ratings
DateFirmRatingTarget
Jul 30, 2026BNP PARIBASNeutral—
Jul 30, 2026ODDO BHFBuy—
Jul 29, 2026PIPER SANDLER COMPANIESNeutral—
Jul 10, 2026ODDO BHFBuy—
Jul 9, 2026ODDO BHFBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

bioMérieux (ENXTPA:BIM) Stock May Be 21% Undervalued Despite FDA Panel Clearance

bioMérieux has had a mixed run, with the share price down over the past year even after a recent rebound, which puts the focus squarely on whether today's valuation lines up with the cash the business is expected to generate. With fresh product news in molecular diagnostics now in the mix, the question is how much of that future cash flow story the current price already reflects. Over the past 12 months the stock has fallen 20.2%, which puts recent price action at odds with the earlier multi...

Yahoo · Oct 8, 2026

bioMérieux (ENXTPA:BIM) Launches SPINCHIP, Is The Stock Fully Priced?

bioMérieux (ENXTPA:BIM) has put its new SPINCHIP point of care platform in front of emergency physicians in Paris, pairing the device with a CE marked high sensitivity cardiac troponin I test. Recent trading suggests investors are reacting positively to news like SPINCHIP, with the share price up 11.30% over 30 days and 12.70% over 90 days. However, the stock is still facing a year-to-date share price return that is down 26.26% and a 1-year total shareholder return that is down 27.11%,...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By